Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations

Marzolini et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01177-20
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Study of Lopinivar and HCQ plasma concentrations and CRP levels in late stage (treatment initiation median 8 days from onset) COVID-19 patients. The median HCQ plasma concentration was 171 ng/ml, which authors suggest indicates that HCQ levels achieved in vivo do not result in adequate clinical activity for COVID-19, however this is incorrect as tissue concentration can be many times higher Ruiz.
Marzolini et al., 8 Jul 2020, peer-reviewed, 18 authors.
This PaperHCQAll
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Catia Marzolini, Felix Stader, Marcel Stoeckle, Fabian Franzeck, Adrian Egli, Stefano Bassetti, Alexa Hollinger, Michael Osthoff, Maja Weisser, Caroline E Gebhard, Veronika Baettig, Julia Geenen, Nina Khanna, Sarah Tschudin-Sutter, Daniel Mueller, Hans H Hirsch, Manuel Battegay, Parham Sendi
Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 g/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (r ϭ 0.37, P Ͻ 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC 50 ) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation.
References
Atzori, Villani, Regazzi, Maruzzi, Cargnel, Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient, AIDS, doi:10.1097/00002030-200307250-00022
Baldelli, Corbellino, Clementi, Cattaneo, Gervasoni, Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?, J Antimicrob Chemother, doi:10.1093/jac/dkaa190
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Choy, Wong, Kaewpreedee, Sia, Chen et al., Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786
Croxtall, Perry, Lopinavir/ritonavir: a review of its use in the management of HIV-1 infection, Drugs, doi:10.2165/11204950-000000000-00000
Dickmann, Patel, Rock, Wienkers, Slatter, Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drugmetabolizing enzymes in human hepatocyte culture, Drug Metab Dispos, doi:10.1124/dmd.111.038679
Dumond, Rigdon, Mollan, Tierney, Kashuba et al., Brief report: significant decreases in both total and unbound lopinavir and amprenavir exposures during coadministration: ACTG Protocol A5143/A5147s results, J Acquir Immune Defic Syndr, doi:10.1097/QAI.0000000000000777
Eichbaum, Blank, Burhenne, Mikus, Concentration effect relationship of CYP3A inhibition by ritonavir in humans, Eur J Clin Pharmacol, doi:10.1007/s00228-013-1530-8
Eron, Feinberg, Kessler, Horowitz, Witt et al., Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial, J Infect Dis, doi:10.1086/380799
Fajgenbaum, Khor, Gorzewski, Tamakloe, Powers et al., Treatments administered to the first 9152 reported cases of COVID-19: a systematic review, Infect Dis Ther, doi:10.1007/s40121-020-00303-8
Fan, Zhang, Liu, Yang, Zheng et al., Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients, Clin Infect Dis, doi:10.1093/cid/ciaa623
Ford, Vitoria, Rangaraj, Norris, Calmy et al., Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment, J Int AIDS Soc, doi:10.1002/jia2.25489
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2012410
Gregoire, Turnier, Gaborit, Veyrac, Lecomte et al., Lopinavir pharmacokinetics in COVID-19 patients, J Antimicrob Chemother, doi:10.1093/jac/dkaa195
Hefner, Shams, Unterecker, Falter, Hiemke, Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels, Psychopharmacology, doi:10.1007/s00213-015-3976-0
Kojima, Yabe, Kaneko, Hirano, Ishikawa et al., Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis, Mod Rheumatol, doi:10.1007/s10165-012-0782-y
Le, Li, Yuan, Shord, Nie et al., FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or lifethreatening cytokine release syndrome, Oncologist, doi:10.1634/theoncologist.2018-0028
Lee, Glaeser, Smith, Roberts, Moeckel et al., Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry, J Biol Chem, doi:10.1074/jbc.M411092200
Markanday, Acute phase reactants in infections: evidence-based review and a guide for clinicians, Open Forum Infect Dis, doi:10.1093/ofid/ofv098
Martin-Blondel, Ruiz, Murris, Faguer, Duhalde et al., Hydroxychloroquine in COVID-19 patients: what still needs to be known about the kinetics, Clin Infect Dis, doi:10.1093/cid/ciaa558
Morgan, Goralski, Piquette-Miller, Renton, Robertson et al., Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer, Drug Metab Dispos, doi:10.1124/dmd.107.018747
Morgan, Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics, Clin Pharmacol Ther, doi:10.1038/clpt.2008.302
Morita, Takahashi, Yoshida, Yokota, Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus, Ther Drug Monit, doi:10.1097/FTD.0000000000000261
Mueck, Kubitza, Becka, Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects, Br J Clin Pharmacol, doi:10.1111/bcp.12075
Nijland, Homme, Rongen, Van Uden, Van Crevel et al., High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets, AIDS, doi:10.1097/QAD.0b013e3282faa71e
Ofotokun, Chuck, Binongo, Palau, Lennox et al., Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy, J Clin Pharmacol, doi:10.1177/0091270007302564
Papanicolaou, Vgontzas, Interleukin-6: the endocrine cytokine, J Clin Endocrinol Metab, doi:10.1210/jcem.85.3.6582
Renton, Regulation of drug metabolism and disposition during inflammation and infection, Expert Opin Drug Metab Toxicol, doi:10.1517/17425255.1.4.629
Schoergenhofer, Jilma, Stimpfl, Karolyi, Zoufaly, Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19), Ann Intern Med, doi:10.7326/m20-1550
Sheahan, Sims, Leist, Schäfer, Won et al., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, doi:10.1038/s41467-019-13940-6
Stader, Khoo, Stoeckle, Back, Hirsch et al., Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interaction effect, J Antmicrob Chemother, doi:10.1093/jac/dkaa253
Stader, Kinvig, Penny, Battegay, Siccardi et al., Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly, Clin Pharmacokinet, doi:10.1007/s40262-019-00822-9
Testa, Prandoni, Paoletti, Morandini, Tala et al., Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience, J Thromb Haemost, doi:10.1111/jth.14871
Tripathy, Dassarma, Roy, Chabalala, Matsabisa, A review on possible modes of actions of chloroquine/hydroxychloroquine: repurposing against SAR-COV-2 (COVID 19) pandemic, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106028
Vreugdenhil, Van Der Velden, Feuth, Kox, Pickkers et al., Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole, Br J Clin Pharmacol, doi:10.1111/bcp.13627
Who, Solidarity" clinical trial for COVID-19 treatments
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA, doi:10.1001/jama.2020.2648
Xu, Zhu, Chan, Lu, Shen et al., Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2, J Pharm Sci, doi:10.1002/jps.24663
Zhang, Li, Shen, Chen, Qi, Rational use of tocilizumab in the treatment of novel coronavirus pneumonia, Clin Drug Invest, doi:10.1007/s40261-020-00917-3
Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ␣-ketoamide inhibitors, Science, doi:10.1126/science.abb3405
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit